startups digital health weight loss glp-1 Chasing the $100 Billion Market for Weight-Loss Drugs 5 Startups Looking to Compete

Metabolic Disord

The economics of these medications have shifted dramatically as shortages have resolved and FDA enforcement on compounding has intensified

Medication alone will not end the obesity epidemic

Current Pharmaceutical Design (2001) This comprehensive clinical review analyzed the physiological rationale and clinical outcomes of pramlintide as amylin replacement therapy in patients with type 1 and type 2 diabetes, framing the approach as hormonal restoration rather than conventional pharmacotherapy

2 It is also a major risk factor for major atherosclerotic cardiovascular events (MACE) and death, which are significantly amplified in the presence of CKD

Key takeaways include: Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026